Aiding and informing the diagnosis of many diseases requires accurate diagnostic tools, many of which require protein (e.g. monoclonal antibody) components for their readouts, and biological manufacturing systems for reagents. Understanding that diagnostic products have a significantly lower demand in terms of scalability and absolute amounts of protein, Aragen routinely scales down the therapeutic CHO-DG44 cell line development process, to enable those requirements in a robust, reproducible and cost-effective manner.